In the participants with obesity and T2DM, weekly GLP-1 RAs (exenatide, dulaglutide, albiglutide, and subcutaneous semaglutide) reduced the risk of MACE versus placebo (RR 0.87 [0.78–0.95]), whereas daily GLP-1 RAs (lixisenatide, liraglutide, and oral semaglutide) did not (RR 0.93 [0.78–1.10]). Here, GLP1R is linked to type 2 diabetes mellitus.